Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Venezuelan President Maduro arrives in New York following U.S. capture: Full coverage - 2Blake Lively's sexual harassment claims against Justin Baldoni dismissed. Where the case stands now.
- 3Where should we send a real 'Hail Mary' spacecraft? A new study has the answers
- 4Deaths reported in Lebanon as Israel and Hezbollah exchange attacks
- 5Flu activity in US could continue to rise for weeks, top CDC epidemiologist says
- Tire Brands for Senior Drivers: Guaranteeing Security and Solace
- Vote In favor of Your Favored Treat
- The Craft of Do-It-Yourself Home Stylistic layout: Change Your Space
- In blow to Lula, Brazil Congress revives controversial environmental bill
- Photos of amputees in Gaza, struggling to survive after losing limbs to Israeli airstrikes
- A Manual for Pick Viable Psychological well-being Backing Administrations In 2024
- The Minimized Passage Horse: Reconsidering a Symbol for the Cutting edge Period
- Pentagon advances Golden Dome missile defense with new Space Force contracts
- Flu season is ramping up, and some experts are "pretty worried"
